Speaker illustration

Doctor Eamon Mulvaney

ATXA Therapeutics Limited, Dublin (Ireland)

The thromboxane receptor antagonist NTP42 improves haemodynamics, inhibits remodelling, and restores function within the cardiopulmonary system in preclinical pulmonary arterial hypertension models

Event: ESC Congress 2021 - The Digital Experience

Topic: Pulmonary Hypertension

Session: Pulmonary circulation, pulmonary embolism, right heart failure e-posters


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb